World-first cancer drugs could work in larger group of patients
A pioneering class of drugs that target cancers with mutations in the BRCA breast cancer genes could also work against tumors with another type of genetic fault, a new study suggests. Scientists found that errors in a gene called CLBC leave cancer cells vulnerable to PARP inhibitor drugs. Around 2 percent of all tumors have defects in CLBC.
